# WideCells Group PLC Licence Award from the Human Tissue Authority

- Link: https://www.directorstalkinterviews.com/widecells-group-plc-licence-award-human-tissue-authority/412746313
- Published: 2018-02-27T07:31:41+00:00
- Author: Giles Arbor

**WideCells Group PLC** (LON:WDC), the healthcare services company focused on providing
stem cell services and ground-breaking insurance for stem cell treatment, has today
announced that the UK’s Human Tissue Authority (“HTA”) has awarded its 100% owned
subsidiary, WideCells Ltd, a Human Application Licence. This licence permits WideCells
Ltd to import, export, process, store and distribute for treatment, umbilical cord
blood and umbilical cord tissue from the UK and Europe in its state of the art facilities
at the Institute of Stem Cell Technology in Manchester, UK.

This transformational milestone licence enables the Group, under its brand name 
BabyCells, to offer umbilical cord blood and tissue storage services to clients 
in the UK and Europe. BabyCells will be charged at a cost of circa £2,000 per sample
for one year’s storage (including collection and processing), with recurring storage
revenues of £50-£75 per annum thereafter and alternative multi-year pre-paid storage
plans. Clients of BabyCells will be offered one year’s stem cell insurance cover,
provided by the Group’s CellPlan division.

> **WideCells Group Plc CEO, João Andrade, said,** “The granting of this licence
> from the HTA marks a significant step in the Group’s end-to-end stem cell service
> solution. WideCells Group can now store and process umbilical cord blood and tissue,
> provide financial cover and support for associated treatment through our innovative
> CellPlan insurance product, and support development and medical advancement within
> the industry through both our research work, and our education and training division
> Wideacademy. This licence enables us to leverage further our significant industry
> contacts and market presence to position our state of the art facility in Manchester
> as a leading stem cell storage bank. The Group is now positioned to focus on revenue
> generation from all three of our divisions.”

Share on: